RSV Vaccine Effective Against Severe RSV-Related LRTI Among Older Adults, Researchers Say

Infectious Disease Advisor (10/18, Chan) reported, “The respiratory syncytial virus (RSV) vaccine Abrysvo® is highly effective against severe RSV-related lower respiratory tract infection (LRTI) among older adults, including those with comorbidities and immunocompromising conditions.” The researchers explained, “This study demonstrated real world VE [vaccine effectiveness] of Abrysvo during its first 5 months of use against severe LRTD in the hospital and ED settings.” The study findings were presented at IDWeek.